Cboe BZX
09:42:27 2024-04-23 am EDT
5-day change
1st Jan Change
2.25
USD
+3.21%
-23.78%
-11.38%
BioAtla, Inc.(NasdaqGM:BCAB) added to S&P Biotechnology Select Industry Index
June 21, 2021 at 12:00 am EDT
BioAtla, Inc.(NasdaqGM:BCAB) added to S&P Biotechnology Select Industry Index
HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating
Mar. 27
MT
Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024
Mar. 26
BioAtla, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Mar. 26
CI
Transcript : BioAtla, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 09:45 AM
Jan. 11
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Dec. 21
MT
Sector Update: Health Care Stocks Advance in Afternoon Trading
Dec. 21
MT
BioAtla Rallies After CEO Buys 50,000 Shares
Dec. 21
MT
Transcript : BioAtla, Inc. - Special Call
Dec. 17
BioAtla, Inc.(NasdaqGM:BCAB) dropped from NASDAQ Biotechnology Index
Dec. 15
CI
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types
Dec. 13
CI
Transcript : BioAtla, Inc. - Special Call
Dec. 13
Sector Update: Health Care Stocks Slipping Tuesday Afternoon
Dec. 05
MT
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy
Dec. 05
MT
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
Dec. 05
CI
Top Premarket Decliners
Nov. 27
MT
HC Wainwright Lowers Price Target on BioAtla to $10 From $17, Maintains Buy Rating
Nov. 08
MT
BioAtla, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 07
CI
Transcript : BioAtla, Inc., Q3 2023 Earnings Call, Nov 07, 2023
Nov. 07
JPMorgan Adjusts BioAtla Price Target to $14 From $17, Maintains Overweight Rating
23-09-25
MT
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-01
CI
Transcript : BioAtla, Inc., Q2 2023 Earnings Call, Aug 01, 2023
23-08-01
BioAtla, Inc.(NasdaqGM:BCAB) added to Russell Small Cap Comp Value Index
23-06-23
CI
BioAtla, Inc.(NasdaqGM:BCAB) added to Russell 3000 Index
23-06-23
CI
BioAtla, Inc.(NasdaqGM:BCAB) added to Russell 3000E Index
23-06-23
CI
BioAtla, Inc.(NasdaqGM:BCAB) added to Russell Small Cap Completeness Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Companyâs product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
More about the company
Last Close Price
2.18
USD
Average target price
11.5
USD
Spread / Average Target
+427.52%
Consensus
1st Jan change
Capi.
-11.38% 105M -0.02% 42.11B +48.77% 40.08B +5.04% 40B -11.32% 26.87B +5.25% 24.58B -23.83% 18.44B -1.62% 11.94B +22.75% 11.66B +6.44% 11.01B
Other Biotechnology & Medical Research
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
BIOATLA, INC. 
